Brian Schreiber

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA.

KPCB China Fund II LP seeks investment opportunities in companies located in China. The fund focuses on companies operating in the fields of health technology, industrial services, and technology services sectors.. It provides financing for seed, early and later-stage capital requirements.

Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD.

INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ.

Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China.

CDI Bioscience, Inc. has developed an innovative technology for increased yield of bioproducts, manufactured in cellular systems. Genetic engineering technology is used to control the metabolism of cells, thus shifting the cell from explicative to production mode (RP Shift®). In particular, this technology has been designed for use in mammalian cells, unlocking their potential to produce proteins, peptides and enzymes. The current design of the technology can be readily translated to bacterial and yeast cellular systems for the production of commercial grade bio products. Recombinant therapeutic proteins have proven to be invaluable biopharmaceuticals for the treatment of chronic and life-threatening diseases. While exceptionally effective, the dosage requirements are generally very high for the required treatment. Several hundred milligrams of protein per administration is common and multiple doses are often required and being protein based drugs, they can only be produced by living cells which is why increasing production yield is a challenge. CDI Bioscience has developed a patented technology that dramatically improves the product yield in biopharmaceutical manufacturing. CDI's core technology, RP Shift®, solves a number of intermediate problems in the development of biopharmaceutical products by significantly boosting the productivity and viability of production cells.

OriGene Technologies, Inc. engages in the development of products for pharmaceutical, biotechnology, and academic research. It offers CDNA clones, antibodies, assay kits, vectors, RNA Interference (RNAi), tissues, proteins, genome editing, and other products. The company was founded by Wei-Wu He in 1996 and is headquartered in Rockville, MD.

GenScript Corp. provides biological research and drug discovery services to pharmaceutical companies. Its products include antibodies, recombinant proteins, protein isolation and analysis, molecular biology reagents, peptides, and cell lines. It offers life sciences research services and preclinical drug development services. The company was founded by Ye Wang, Fang Liang Zhang, and Lu Quan Wang in 2002 and is headquartered in Piscataway, NJ.

Inomax LLC is an American venture capital company.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA.

The Capital Network, Inc. is a private company based in Wellesley, MA that provides founder-focused fundraising education programs. The company aims to create a more inclusive and accessible funding ecosystem to support female and other first-time founders of early stage startups. The company offers three programs: the Fellowship for Female Founders, Fundraising Readiness Workshops, and the Investment and Inclusion Series. The Fellowship for Female Founders is a six-month program that has helped over 90+ female founders raise over $85m in capital. The company also offers ongoing workshops for first-time startup founders and a series of honest conversations to bring about meaningful systemic change. The Capital Network has a network of 300+ investors and sponsors who help them make the fundraising ecosystem work for everybody. The company was founded by Ashkan Afkhami and Chula Reynolds.

OMNI Pharmaceuticals (USA), Inc. is a private company based in Pembroke Pines, FL.

CVie Therapeutics Co., Ltd. manufactures drugs to treat hypertension and acute heart failure. The private company is based in Hong Kong, Hong Kong.

Smooth Prosper Ltd. is a Chinese company that manufactures and sells surgical devices.

Xwpharma operates as a biopharmaceutical company. It focuses on eveloping a portfolio of internally discovered product candidates for the treatment of neurological disorders. The company was founded by Jia-Ning Xiang and is headquartered in Wuhan, China.

Adaptive Phage Therapeutics, Inc. provides therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. The company was founded by Gregory L. Merril and Carl R. Merril and is headquartered in Bethesda, MD.

Kleiner Perkins Caufield & Byers China is a venture capital and investment advisory firm based in Beijing, China.

Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA.

Tactiva Therapeutics LLC operates as a development stage immuno-oncology company. The firm engages in developing the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. The company was founded by Matthew E. Colpoys Jr., Richard C. Koya, and Kunle Odunsi and is headquartered in Buffalo, NY.

Chime Biologics Ltd. is a leading Contract Development and Manufacturing Organization (CDMO) that provides customer-centric and cost-effective outsourcing services for biopharmaceutical development and manufacturing. The company is based in Wuhan, China, and its world's first GE Kubio facility is located at Wuhan's Bio-Lake Biotech Industry Development Zone, with a clear path to expand the total capacity up to 140,000+ liters in the near future. The Chinese company has introduced the world's first modular biopharmaceutical plant, Kubio, which empowers its partners' success in biologics from cell line development to commercial manufacturing. Chime Biologics is committed to making cutting-edge biomedicines affordable and accessible to all patients, fulfilling its commitment to human health. Chime Biologics is ISO 14001:2015 and ISO 45001:2018 certified and has been providing customers with clinical materials for pre-clinical and clinical stages worldwide since 2016.